Description
OlmesartanmedoxomilisanangiotensinIItype1receptor(AT1)inhibitorthatinhibitsnegativeregulatoryfeedbackonreninsecretion,decreasingsecretionofaldosteroneandresultingindecreasedperipheralvascularresistance(vasodilation).Thiscompoundexhibitsantihypertensive,cardioprotective,vasodilatory,andanti-inflammatoryactivities.Duetothisaction,olmesartanincreasescerebralbloodflowandcerebrovascularreservecapacityinhypertensivestrokepatients.Additionally,thiscompoundimprovescardiacfunctionthroughactivationoftheDLL4/Notch1signalingpathwayinanimalmodelsofchroniccardiacpressureoverload.Olmesartanalsoinhibitsactivationofapoptosissignalregulatingkinase1(ASK1)inanimalmodelsofdiabetes,attenuatingcardiacinflammationandvascularendothelialdysfunction.
References
YouJ,WuJ,JiangG,etal.OlmesartanattenuatescardiacremodelingthroughDLL4/Notch1pathwayactivationinpressureoverloadmice.JCardiovascPharmacol.2013Feb;61(2):142-51.PMID:23188126.
VerdecchiaP,AngeliF,RepaciS,etal.Comparativeassessmentofangiotensinreceptorblockersindifferentclinicalsettings.VascHealthRiskManag.2009;5:939-48.PMID:19997575.
MatsumotoS,ShimodozonoM,MiyataR,etal.BenefitsoftheangiotensinIIreceptorantagoNISTolmesartanincontrollinghypertensionandcerebralhemodynamicsafterstroke.HypertensRes.2009Nov;32(11):1015-21.PMID:19745828.
YamamotoE,DongYF,KataokaK,etal.Olmesartanpreventscardiovascularinjuryandhepaticsteatosisinobesityanddiabetes,accompaniedbyapoptosissignalregulatingkinase-1inhibition.Hypertension.2008Sep;52(3):573-80.PMID:18678790.
BrousilJA,BurkeJM.Olmesartanmedoxomil:anangiotensinII-receptorblocker.ClinTher.2003Apr;25(4):1041-55.PMID:12809956.